Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had its price target upped by research analysts at Cowen and Company from $31.00 to $34.00 in a report released on Thursday, May 11th. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Cowen and Company’s target price points to a potential downside of 12.03% from the company’s previous close.
SUPN has been the topic of several other research reports. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 4th. Cantor Fitzgerald restated a “buy” rating and set a $32.00 price target on shares of Supernus Pharmaceuticals in a report on Thursday, January 12th. Jefferies Group LLC set a $35.00 price target on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 10th. Finally, Stifel Nicolaus increased their price objective on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, April 3rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $33.43.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at 38.65 on Thursday. The stock’s 50 day moving average is $35.55 and its 200-day moving average is $29.14. The company has a market cap of $1.94 billion, a PE ratio of 20.79 and a beta of 1.76. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $41.35.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. Supernus Pharmaceuticals had a return on equity of 20.76% and a net margin of 17.88%. The company had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.91 million. Equities research analysts expect that Supernus Pharmaceuticals will post $1.08 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Cowen and Company Increases Supernus Pharmaceuticals Inc (SUPN) Price Target to $34.00” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/06/17/supernus-pharmaceuticals-inc-supn-given-new-34-00-price-target-at-cowen-and-company-updated-updated-updated.html.
In related news, VP Padmanabh P. Bhatt sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $39.86, for a total transaction of $398,600.00. Following the transaction, the vice president now owns 27,500 shares in the company, valued at approximately $1,096,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $35.90, for a total value of $89,750.00. Following the sale, the vice president now directly owns 37,500 shares of the company’s stock, valued at $1,346,250. The disclosure for this sale can be found here. Insiders have sold a total of 83,806 shares of company stock worth $2,813,038 in the last 90 days. 6.70% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of SUPN. BlackRock Inc. boosted its stake in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $21,772,000. AXA acquired a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $6,519,000. BlackRock Institutional Trust Company N.A. boosted its stake in Supernus Pharmaceuticals by 16.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,149,244 shares of the specialty pharmaceutical company’s stock valued at $28,421,000 after buying an additional 165,346 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after buying an additional 156,094 shares in the last quarter. 92.17% of the stock is owned by institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
What are top analysts saying about Supernus Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc and related companies.